Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC Cinryze with rHuPH20 in HAE
NCT01426763Phase 2Completed
- Sponsor
- Takeda
- Start
- Sep 2011
- Primary completion
- Nov 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of c1-esterase inhibitor in hereditary angioedema (HAE) (2 arms), sponsored by Takeda. Primary endpoints: Incidence and Severity of Adverse Events at 18 days, Number of Participants With Local Injection Site Reactions at 18 days and 1 more. Started Sep 2011; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT01426763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01426763.